Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Improving Outcomes in Diabetic Nephropathy
NCT00381134Phase 2Completed
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases
- Start
- Jul 2003
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of losartan and spironolactone in diabetic nephropathy (DN) (3 arms), sponsored by National Institute of Diabetes and Digestive and Kidney Diseases. Primary endpoint: Change in 24 hour urine albumin to creatinine ratio at 12 months. Started Jul 2003; status: completed.
02
Drugs
losartanspironolactone
03
Conditions
diabetic nephropathy (DN)
Beyond the preview
Go deeper on NCT00381134.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00381134.